16 Jan 2025 Avacta Announces Positive New Data from the AVA6000 Phase 1 trial Demonstrating Clinically Meaningful Tumor Shrinkage in Patients with Salivary Gland Cancers Investors | Therapeutics
17 Dec 2024 Research & Development Spotlight Series – Episode 7 Investors | R&D Spotlights Series | Therapeutics
12 Dec 2024 Dose Escalation and Recommended Dose for Expansion (RDE) Arms of the AVA6000 Phase 1a Trial complete and Phase 1b Disease Specific Expansion Cohorts Open for Enrolment Investors | Therapeutics
27 Nov 2024 Peel Hunt Healthcare & Life Sciences Podcast with Christina Coughlin Investors | Therapeutics
08 Nov 2024 Video presentations from R&D Spotlight: ‘Next Generation of pre|CISION® Medicines’ Investors | R&D Spotlights Series | Therapeutics
24 Oct 2024 Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona Investors | Therapeutics